Beijing InnoFuture Biopharmaceutical Technology

Beijing Inno Medicine is a clinical-stage biopharmaceutical company specializing in the development of targeted nanomedicines for cardiovascular diseases, with a primary focus on atherosclerosis. Founded in 2016 and based in Beijing's Daxing District, the company utilizes a proprietary active targeted liposome technology platform to deliver therapeutic agents directly to atherosclerotic plaques, aiming to provide non-invasive alternatives to coronary stenting and bypass surgery. Its lead programs include innovative targeted therapies for moderate-to-severe atherosclerosis and myocardial infarction, developed in collaboration with institutions like Beijing Anzhen Hospital. The company has established a comprehensive R&D and manufacturing infrastructure, supported by significant venture capital funding from investors such as Saiying Capital.